Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Tacrolimus: a further update of its use in the management of organ transplantation.
The reduced incidence of rejection episodes in renal transplant recipients receiving tacrolimus translated into a better cost effectiveness relative to cyclosporin microemulsion treatment, which was reflected in improved cost effectiveness.
Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.
Tacrolimus is an important therapeutic option for the optimal individualisation of immunosuppressive therapy in transplant recipients and may well be an influential factor in selecting the optimal treatment for patients undergoing organ transplantation.
Tocilizumab: a review of its use in the management of rheumatoid arthritis.
Tocilizumab-based therapy was consistently more effective than placebo, methotrexate or other DMARDs in reducing disease activity, and some trials also showed significant benefits with tocilizumAB in terms of reducing structural joint damage and improving health-related quality of life (HR-QOL).
Nelfinavir: an update on its use in HIV infection.
Nelfinavir is effective in limiting HIV replication and increasing CD4+ cell counts in HIV-infected adults and children and should be considered as a first-line option in protease inhibitor-naive patients and in those unable to tolerate other protease inhibitors.
Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Atomoxetine is an effective and generally well tolerated treatment for adults with ADHD and is particularly useful in patients who are at risk for substance abuse or who do not wish to take a controlled substance.
Dapagliflozin: a review of its use in type 2 diabetes mellitus.
- G. Plosker
- 3 December 2012
Dapagliflozin was generally well tolerated in clinical trials of 24 or 52 weeks duration and in extension studies of up to ≈2 years, and appears to be an important addition to the therapeutic options for the management of type 2 diabetes, particularly when used as add-on therapy.
Olanzapine: an updated review of its use in the management of schizophrenia.
Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in thetreatment of some patients with first-episode or treatment-resistant schizophrenia.
Amisulpride: a review of its use in the management of schizophrenia.
Oral amisulpride is an effective and well tolerated option for the first-line treatment of patients with acute schizophrenia as well as for those requiring long-term maintenance therapy and does not seem to be associated with diabetogenic effects.
Pioglitazone: a review of its use in type 2 diabetes mellitus.
In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin or a sulphonylurea, induced both long- and short-term improvements in glycaemic control and serum lipid profiles.
Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
Oral tenofovir DF 300 mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive.